enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium [Yahoo! Finance]
enVVeno Medical Corporation (NVNO)
Company Research
Source: Yahoo! Finance
meaningful benefit responder rate, 75% median reduction in pain, and 87% median ulcer area reduction. The data supports the company's application for pre-market authorization from the FDA. The VenoValve, a surgical replacement venous valve, is being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI), a debilitating disease with no effective treatments. The company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. 85% Clinical Meaningful Benefit Responder Rate 7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort 75% Median Reduction in Pain (VAS) 87% Median Ulcer Area Reduction 97% Target Vein Patency Rate Improvement in All Patient Reported Quality-of-Life Indicators Company to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / Novem
Show less
Read more
Impact Snapshot
Event Time:
NVNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVNO alerts
High impacting enVVeno Medical Corporation news events
Weekly update
A roundup of the hottest topics
NVNO
News
- enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH SymposiumAccesswire
- enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval [Yahoo! Finance]Yahoo! Finance
- enVVeno Medical Submits the VenoValve PMA Application Seeking FDA ApprovalAccesswire
- Coronary Artery Bypass Graft Surgery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Report [Yahoo! Finance]Yahoo! Finance
- enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this YearAccesswire
NVNO
Sec Filings
- 11/19/24 - Form DEF
- 11/14/24 - Form SCHEDULE
- 11/14/24 - Form SC
- NVNO's page on the SEC website